Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BDX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Evaluation of Catheter Utilization in Female Patients Using Indwelling Urinary Catheters and the Pu… NCT07798128 · Urinary Incontinence, Limited Mobility PureWick™ Flex Female External Catheter (FFEC), Indwelling… | BDX Becton, Dickinson and Company | — | Not yet recruiting | 240 | Jun 30, 2027 | Registry ↗ |
| Oct 21, 2026 | This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine… NCT06850259 · Urinary Incontinence PureWick® Urine Collection System, UltraFlex™ Self-Adhering… | BDX C. R. Bard | Not applicable | Completed | 15 | Jun 15, 2025 | Registry ↗ |
| Oct 19, 2026 | Prophylactic Reinforcement of Ventral Abdominal Incisions Trial NCT03911700 · Open Midline Laparotomy Phasix™ Mesh | BDX C. R. Bard | Not applicable | Active, not recruiting | 477 | Aug 2028 | Registry ↗ |
| Oct 2, 2026 | Evaluation of Male and Female External Catheters for Urine Output Monitoring in the ICU NCT07744945 · Urine Output, ICU Patients Indwelling Urinary Catheter, External Urinary Catheter | BDX C. R. Bard | — | Enrolling by invitation | 32 | Oct 2026 | Registry ↗ |
| Sep 25, 2026 | Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmenta… NCT05945329 · Capsular Contracture Associated With Breast Implant, Capsul… GalaFLEX LITE™ Scaffold, Standard surgery | BDX C. R. Bard | Not applicable | Recruiting | 250 | Feb 2029 | Registry ↗ |
| Aug 27, 2026 | The BD Liverty™ TIPS Stent Graft Study NCT05711316 · Portal Hypertension, TIPS BD Liverty™ TIPS Stent Graft | BDX C. R. Bard | Not applicable | Active, not recruiting | 177 | Jun 23, 2025 | Registry ↗ |
| Aug 26, 2026 | HemoSphere Alta Study NCT07148323 · Hemodynamic Instability HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial ca… | BDX Becton, Dickinson and Company | — | Recruiting | 100 | Nov 2026 | Registry ↗ |
| Aug 10, 2026 | Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System NCT04634916 · Kidney Disease, End-Stage, End-stage Renal Disease EndoAVF Creation | BDX C. R. Bard | Not applicable | Recruiting | 220 | Jun 2027 | Registry ↗ |
| Aug 4, 2026 | An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in… NCT07282860 · Urinary Incontinence PureWick System, UltraFlex Self-Adhering Male External Cath… | BDX C. R. Bard | Not applicable | Completed | 120 | Jun 22, 2026 | Registry ↗ |
| Jul 13, 2026 | UK PureWick™ At-Home Pilot Study NCT07555548 · Urinary Incontinence Treatment with the PureWick™ Urine Collection System Extern… | BDX Becton, Dickinson and Company | — | Recruiting | 95 | Nov 2026 | Registry ↗ |
| Jul 8, 2026 | ClearSight NextGen1 Study NCT07317648 · Blood Pressure ClearSight NextGen system | BDX Becton, Dickinson and Company | Not applicable | Completed | 35 | Mar 5, 2026 | Registry ↗ |
| Jul 8, 2026 | The Continuity Study NCT07216573 · Blood Pressure HemoSphere Vita Monitor with VitaWave or VitaWave Plus Fing… | BDX Becton, Dickinson and Company | Not applicable | Recruiting | 188 | Jan 2027 | Registry ↗ |
| Jul 8, 2026 | Personal BP - CAI Study NCT06492746 · Blood Pressure HemoSphere Advanced Monitoring Platform with Acumen IQ sens… | BDX Becton, Dickinson and Company | Not applicable | Recruiting | 120 | Jan 2027 | Registry ↗ |
| Jul 8, 2026 | SMART TRENDS Study NCT05957406 · Moderate to High-risk Noncardiac Surgery Acumen HPI Smart Alerts and Smart Trends Software, The Hemo… | BDX Becton, Dickinson and Company | Not applicable | Completed | 296 | Oct 27, 2025 | Registry ↗ |
| May 1, 2026 | Investigational Study With the BD PosiFlush™ SafeScrub on NADs NCT06604026 · CRBSI - Catheter Related Bloodstream Infection BD PosiFlush™ SafeScrub, BD PosiFlush™ | BDX Becton, Dickinson and Company | Not applicable | Completed | 222 | Apr 30, 2026 | Registry ↗ |
| Mar 18, 2026 | Venclose digiRF System Post Market Study NCT05504070 · Venous Reflux, Chronic Venous Insufficiency Venclose System (digiRF generator w EVSRF catheter), Venclo… | BDX C. R. Bard | Not applicable | Active, not recruiting | 203 | Jul 17, 2025 | Registry ↗ |
| Mar 18, 2026 | Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteri… NCT03506308 · Arteriovenous Fistula LUTONIX 035 Drug Coated Balloon PTA Catheter | BDX C. R. Bard | Not applicable | Active, not recruiting | 213 | Apr 2027 | Registry ↗ |
| Feb 10, 2026 | Observational Study of TissuePatch SF in Prevention of Air Leaks Following Lung Resection NCT06934486 · Post-operative Air Leaks TissuePatch Sealant Film | BDX C. R. Bard | — | Not yet recruiting | 250 | Feb 1, 2028 | Registry ↗ |
| Jan 16, 2026 | BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical… NCT06632496 · BD Prevue II for Peripheral Intravenous Catheter Placement BD Prevue(TM) II | BDX Becton, Dickinson and Company | — | Completed | 156 | Sep 23, 2025 | Registry ↗ |
| Jan 15, 2026 | BD SiteRite(TM) 9 Ultrasound System - Clinical Study NCT06632509 · BD SiteRite 9 for VAD Insertion BD SiteRite(TM) 9 | BDX Becton, Dickinson and Company | — | Completed | 149 | Jan 9, 2026 | Registry ↗ |
| Dec 22, 2025 | Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries NCT05556681 · Peripheral Arterial Disease, Peripheral Artery Disease BD™ Sirolimus Drug Coated Balloon Catheter percutaneous tra… | BDX C. R. Bard | Not applicable | Completed | 34 | Jun 12, 2024 | Registry ↗ |
| Dec 19, 2025 | Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Por… NCT06669806 · Portal Hypertension Related to Cirrhosis, Ascites Hepatic TIPS Stent Graft | BDX C. R. Bard | Not applicable | Recruiting | 166 | Jun 1, 2026 | Registry ↗ |
| Dec 19, 2025 | Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories. NCT05953363 · Anesthesia, Analgesia BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needl… | BDX Becton, Dickinson and Company | — | Completed | 161 | May 28, 2024 | Registry ↗ |
| Dec 17, 2025 | Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry) NCT07016698 · Peripheral Arterial Disease(PAD) Rotarex(TM) Rotational Excisional Atherectomy System | BDX C. R. Bard | Not applicable | Recruiting | 600 | Mar 31, 2029 | Registry ↗ |
| Dec 16, 2025 | Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft NCT04261686 · Arteriovenous Fistula Covera Vascular Covered Stent | BDX C. R. Bard | Not applicable | Completed | 100 | Sep 16, 2025 | Registry ↗ |
| Dec 11, 2025 | everlinQ Endovascular Access System Enhancements (EASE) Study NCT03708770 · Chronic Kidney Diseases everlinQ endoAVF System | BDX C. R. Bard | Not applicable | Completed | 32 | Jun 19, 2017 | Registry ↗ |
| Dec 11, 2025 | everlinQ Endovascular Access Systems Enhancements (EASE-2) Study NCT03708562 · Chronic Kidney Diseases everlinQ endoAVF System | BDX C. R. Bard | Not applicable | Completed | 24 | Dec 12, 2018 | Registry ↗ |
| Dec 11, 2025 | Evaluating Safety and Effectiveness of Octenidine Dihydrochloride NCT03140254 · Preoperative Skin Preparation Chlorhexidine gluconate, N,N'-(1,10-decanediyldi-1(4H)-Pyri… | BDX C. R. Bard | Phase 2 | Completed | 145 | Mar 17, 2017 | Registry ↗ |
| Dec 11, 2025 | everlinQ endoAVF Post Market Study NCT02682420 · Chronic Kidney Disease everlinQ endoAVF System | BDX C. R. Bard | Not applicable | Terminated | 100 | Aug 2019 | Registry ↗ |
| Dec 11, 2025 | Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved… NCT02649894 · Malignant Pleural Effusion Active Comparator: Approved Uncoated PleurX Indwelling Pleu… | BDX C. R. Bard | Not applicable | Completed | 119 | Apr 18, 2018 | Registry ↗ |
| Dec 11, 2025 | Topical Antimicrobial Effectiveness Testing NCT01366417 · Antimicrobial Effectiveness ChloraPrep One-Step, 70% isopropyl alcohol | BDX C. R. Bard | Phase 4 | Completed | 25 | Jun 2011 | Registry ↗ |
| Dec 11, 2025 | Topical Antimicrobial Effectiveness Testing NCT01314703 · Antimicrobial Effectiveness ChloraPrep One-Step, 70% isopropyl alcohol | BDX C. R. Bard | Phase 4 | Completed | 27 | Apr 2011 | Registry ↗ |
| Dec 11, 2025 | Test for Pre Operative Skin Preparations NCT00799812 · Topical Antisepsis CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once)., CHG 2% w/v… | BDX C. R. Bard | Phase 3 | Completed | 335 | Apr 27, 2008 | Registry ↗ |
| Nov 26, 2025 | A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Man… NCT02227732 · Malignant Pleural Effusions New Indwelling Pleural Catheter | BDX C. R. Bard | Not applicable | Completed | 10 | May 2015 | Registry ↗ |
| Nov 26, 2025 | A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol FLEX-1-… NCT02119845 · Chronic Kidney Disease (CKD) Endovascular AVF (EndoAVF) | BDX C. R. Bard | Not applicable | Completed | 16 | Apr 2013 | Registry ↗ |
| Nov 26, 2025 | A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-… NCT02119832 · Chronic Kidney Disease (CKD) Endovasccular AVF (EndoAVF) | BDX C. R. Bard | Not applicable | Completed | 17 | Feb 2014 | Registry ↗ |
| Nov 26, 2025 | Novel Endovascular Access Trial (NEAT) NCT02036671 · Chronic Kidney Disease The FLEX System will be used to percutaneously create a fis… | BDX C. R. Bard | Not applicable | Completed | 80 | Dec 2015 | Registry ↗ |
| Nov 26, 2025 | Components of Chlorhexidine Gluconate Dressing NCT01112020 · Healthy CHG Catheter Dressing Patch, Biopatch | BDX C. R. Bard | Phase 1 | Completed | 45 | May 2010 | Registry ↗ |
| Nov 26, 2025 | Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics NCT00692484 · Healthy Chlorhexidine gluconate, Povidone iodine | BDX C. R. Bard | Phase 3 | Completed | 122 | Feb 2008 | Registry ↗ |
| Nov 26, 2025 | Preoperative Skin Preparation Evaluation NCT00636480 · Topical Antisepsis Chlorhexidine gluconate, ChloraPrep One Step | BDX C. R. Bard | Phase 3 | Completed | 60 | Mar 2008 | Registry ↗ |
| Nov 20, 2025 | Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent Product NCT06426121 · Sepsis test Aerobic/F Culture Vials, control Aerobic/F Culture Via… | BDX Becton, Dickinson and Company | — | Completed | 394 | Oct 23, 2025 | Registry ↗ |
| Oct 20, 2025 | PureWick™ Adolescent Study NCT06631313 · Healthy Volunteers, Adolescent PureWick System | BDX C. R. Bard | Not applicable | Completed | 43 | Sep 10, 2024 | Registry ↗ |
| Jul 24, 2025 | This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring U… NCT06666426 · Adult Nocturnal Enuresis, Urinary Incontinence (UI) PureWick System, Hollister Female Urinary Pouch External Co… | BDX C. R. Bard | Not applicable | Completed | 171 | Jun 30, 2025 | Registry ↗ |
| Jul 16, 2025 | PureWick™ France and U.S. At-Home Pilot Study NCT05710718 · Nocturnal Enuresis PureWick™ System, Hollister® Female Urinary Pouch External… | BDX C. R. Bard | Not applicable | Completed | 17 | Aug 25, 2024 | Registry ↗ |
| Jul 2, 2025 | Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay Kit NCT04461678 · Cervical Cancer HPV Genotyping Nucleic Acid Assay Kit | BDX Becton, Dickinson and Company | Not applicable | Completed | 12,230 | Aug 26, 2024 | Registry ↗ |
| Feb 3, 2025 | Investigational On-body Injector Clinical Study NCT05553418 · Healthy Volunteers In-clinic wear first, Home wear first | BDX Becton, Dickinson and Company | Not applicable | Completed | 70 | Feb 8, 2023 | Registry ↗ |
| Jan 27, 2025 | A Post-Market Clinical Follow Up Study to Evaluate BD PureHub™ Disinfecting Cap Use on Needle-Free… NCT05130762 · Catheter Related Complication, Vascular Access Site Managem… BD PureHub™ Disinfecting Cap Placements: Attachments/remova… | BDX Becton, Dickinson and Company | Not applicable | Completed | 157 | May 22, 2023 | Registry ↗ |
| Jan 16, 2025 | The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation NCT04626427 · End Stage Kidney Disease, Chronic Kidney Diseases WavelinQ™ EndoAVF System | BDX C. R. Bard | Not applicable | Terminated | 21 | Jun 15, 2022 | Registry ↗ |
| Sep 26, 2024 | BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System. NCT05557422 · Chronic Lymphoproliferative Diseases (CLPD) BD OneFlow LST, and B-CLPD T1 to T4 Assays | BDX Becton, Dickinson and Company | — | Completed | 322 | May 8, 2024 | Registry ↗ |
| Sep 19, 2024 | Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles NCT01231984 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle | BDX Becton, Dickinson and Company | Not applicable | Completed | 293 | May 2012 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances